Tessa Therapeutics Establishes New Scientific Advisory Board

Date: 22 May 2019 

Tessa Therapeutics has established a new Scientific Advisory Board (SAB) with the appointment of a team of highly respected scientists, practicing clinicians and industry veterans. These appointments come at an important stage of the company’s growth, as Tessa looks to advance and broaden our cell therapy portfolio.

The new SAB is chaired by Dr. Giulio Draetta, Senior Vice President and Chief Scientific Officer at The University of Texas MD Anderson Cancer Center, and comprises a line-up of distinguished members whose deep industry knowledge and extensive leadership experience will be hugely valuable in guiding and supporting Tessa for future growth.

Learn more about our SAB members here.